AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial Repare cans plans for phase 3 cancer combo trial in latest money-saving move Novo Holdings-backed Windward generates $200M series A, inks $970M biobucks deal for clinical antibody Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work Biotech creator and China's Keymed launch antibody company with $180M series A GSK-backed Ouro Medicines launches into T-cell engager space with $120M and clinical-stage asset Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect Moderna co-founder Kenneth Chien's new biotech inks $950M RNA deal with Etherna Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO Fierce Biotech Fundraising Tracker '25: Numab tacks on $54M; Leyden Labs lands $70M Fierce Biotech Layoff Tracker 2025: Y-mAbs reduces workforce by up to 13%; Repare deepens cuts | 